Todd M Tuttle

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/767202/publications.pdf

Version: 2024-02-01

167 papers

9,218 citations

43973 48 h-index 93 g-index

170 all docs

170 docs citations

170 times ranked

8281 citing authors

#	Article	IF	CITATIONS
1	ASO Visual Abstract: Oncologic Outcomes of Multi-Institutional Minimally Invasive Inguinal Lymph Node Dissection for Melanoma Compared with Open Inguinal Dissection in MSLT-II. Annals of Surgical Oncology, 2022, , 1.	0.7	o
2	Oncologic Outcomes of Multi-Institutional Minimally Invasive Inguinal Lymph Node Dissection for Melanoma Compared with Open Inguinal Dissection in the Second Multicenter Selective Lymphadenectomy Trial (MSLT-II). Annals of Surgical Oncology, 2022, , 1.	0.7	4
3	Surgical applications of ultrasound use in lowâ€Âand <scp>middleâ€income</scp> countries: A systematic review. Australasian Journal of Ultrasound in Medicine, 2022, 25, 80-97.	0.3	1
4	The Addition of Chemoradiation to Adjuvant Chemotherapy is Associated With Improved Survival Following Upfront Surgical Resection for Pancreatic Cancer With Nodal Metastases. Cancer Control, 2022, 29, 107327482211099.	0.7	0
5	Chemotherapy refusal and subsequent survival in older women with high genomic risk, estrogen receptor–positive breast cancer Journal of Clinical Oncology, 2022, 40, 520-520.	0.8	o
6	The use of national datasets to evaluate outcomes for invasive lobular carcinoma. Cancer, 2022, 128, 3416-3417.	2.0	0
7	Surgeon decisionâ€making for management of positive sentinel lymph nodes in the postâ€Multicenter Selective Lymphadenectomy Trial II era: A survey study. Journal of Surgical Oncology, 2021, 123, 646-653.	0.8	12
8	Synchronous breast carcinoma and peritoneal mesothelioma. Breast Journal, 2021, 27, 550-552.	0.4	1
9	Omitting Sentinel Lymph Node Biopsy in Elderly Patients: A Lost Opportunity?. Annals of Surgical Oncology, 2021, 28, 5442-5443.	0.7	1
10	Genetic Testing and De-escalation of Contralateral Prophylactic Mastectomy. Annals of Surgical Oncology, 2021, 28, 4764-4766.	0.7	2
11	Travel, Treatment Choice, and Survival Among Breast Cancer Patients: A Population-Based Analysis. Women S Health Reports, 2021, 2, 1-10.	0.4	11
12	The 70-gene signature test as a prognostic and predictive biomarker in patients with invasive lobular breast cancer. Breast Cancer Research and Treatment, $2021, 1.$	1.1	9
13	Intraoperative inking is superior to suture marking for specimen orientation in breast cancer. Breast Journal, 2020, 26, 661-667.	0.4	4
14	Evaluating Travel Distance to Radiation Facilities Among Rural and Urban Breast Cancer Patients in the Medicare Population. Journal of Rural Health, 2020, 36, 334-346.	1.6	31
15	Academic Partnerships in Global Surgery. Annals of Surgery, 2020, 271, 460-469.	2.1	25
16	Genomic expression assay testing among American Indian and Alaska Native women with breast cancer. Cancer, 2020, 126, 5222-5229.	2.0	2
17	Social Media Perceptions of Surgical Cancer Care in the Era of COVID-19: A Global Cross-Sectional Study. JCO Global Oncology, 2020, 6, 1306-1311.	0.8	2
18	Adjuvant chemotherapy for intrahepatic cholangiocarcinoma: approaching clinical practice consensus?. Hepatobiliary Surgery and Nutrition, 2020, 9, 577-586.	0.7	14

#	Article	IF	Citations
19	The addition of chemoradiation to adjuvant chemotherapy is associated with improved survival in lymph node-positive gastric cancer. Surgical Oncology, 2020, 34, 134-139.	0.8	3
20	Systemic therapy without radiation may be appropriate as neoadjuvant therapy for localized pancreas cancer. Hepatobiliary Surgery and Nutrition, 2020, 9, 296-303.	0.7	4
21	Minimally invasive microwave ablation provides excellent longâ€term outcomes for otherwise inaccessible hepatocellular cancer. Journal of Surgical Oncology, 2020, 121, 1218-1224.	0.8	4
22	Identifying New Frontiers for Social Media Engagement in Global Surgery: An Observational Study. World Journal of Surgery, 2020, 44, 2881-2891.	0.8	8
23	21-gene recurrence score testing in the older population with estrogen receptor-positive breast cancer. Journal of Geriatric Oncology, 2019, 10, 322-329.	0.5	27
24	Completion of Adjuvant Chemotherapy After Upfront Surgical Resection for Pancreatic Cancer Is Uncommon Yet Associated With Improved Survival. Annals of Surgical Oncology, 2019, 26, 4108-4116.	0.7	83
25	Incidence and predictors of incisional hernia after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. International Journal of Hyperthermia, 2019, 36, 811-815.	1.1	4
26	Letter of response re: The use of indocyanine green angiography in postmastectomy reconstruction: Do outcomes improve over time?. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2019, 72, 1576-1606.	0.5	0
27	The use of indocyanine green angiography in postmastectomy reconstruction: Do outcomes improve over time?. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2019, 72, 548-554.	0.5	13
28	The use of contralateral prophylactic mastectomy among elderly patients in the United States. Breast Cancer Research and Treatment, 2019, 177, 175-183.	1.1	9
29	Trends in lobular carcinoma in situ management: endocrine therapy use in California and New Jersey. Cancer Causes and Control, 2019, 30, 129-136.	0.8	1
30	Surgical resection of lymph node positive intrahepatic cholangiocarcinoma may not improve survival. Hpb, 2019, 21, 235-241.	0.1	28
31	21-Gene Recurrence Score Testing in HER2-positive Patients. Clinical Breast Cancer, 2019, 19, 126-130.	1.1	2
32	Quality-of-life implications of risk-reducing cancer surgery. British Journal of Surgery, 2018, 105, e121-e130.	0.1	15
33	Distribution of 21-Gene Recurrence Scores Among Breast Cancer Histologic Subtypes. Archives of Pathology and Laboratory Medicine, 2018, 142, 735-741.	1.2	13
34	Global Surgery: Effective Involvement of US Academic Surgery. Annals of Surgery, 2018, 268, 557-563.	2.1	15
35	Tumor grade and progesterone receptor status predict 21-gene recurrence score in early stage invasive breast carcinoma. Breast Cancer Research and Treatment, 2018, 172, 671-677.	1.1	18
36	Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint. Npj Breast Cancer, 2018, 4, 26.	2.3	24

#	Article	IF	Citations
37	Distribution of 21-Gene Recurrence Scores in Male Breast Cancer in the United States. Annals of Surgical Oncology, 2018, 25, 2296-2302.	0.7	9
38	Reply to Elderly patients diagnosed with hepatopancreatobiliary malignancies: A challenge beyond resection. Cancer, 2017, 123, 890-891.	2.0	0
39	Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast. Cancer, 2017, 123, 3015-3021.	2.0	54
40	Venturing Out on a Limb: Axillary Web Syndrome. American Journal of Medicine, 2017, 130, e209-e210.	0.6	5
41	Prognostic Factors for Metachronous Contralateral Breast Cancer: Implications for Management of the Contralateral Breast. Breast Journal, 2017, 23, 299-306.	0.4	5
42	Prognostic factors for survival in advanced appendiceal cancers. Cancer Biomarkers, 2017, 17, 457-462.	0.8	8
43	Impact of the 21-gene recurrence score on outcome in patients with invasive lobular carcinoma of the breast. Breast Cancer Research and Treatment, 2017, 165, 757-763.	1.1	49
44	Survival Rates for Patients with Resected Gastric Adenocarcinoma Finally have Increased in the United States. Annals of Surgical Oncology, 2017, 24, 3361-3367.	0.7	11
45	Guidelines for Guidelines: An Assessment of the American Society of Breast Surgeons Contralateral Prophylactic Mastectomy Consensus Statement. Annals of Surgical Oncology, 2017, 24, 1-2.	0.7	32
46	Completion Lymph Node Dissection or Observation for Melanoma Sentinel Lymph Node Metastases: A Decision Analysis. Annals of Surgical Oncology, 2016, 23, 2772-2778.	0.7	6
47	Postmastectomy Reconstruction Outcomes After Intraoperative Evaluation with Indocyanine Green Angiography Versus Clinical Assessment. Annals of Surgical Oncology, 2016, 23, 4080-4085.	0.7	50
48	A comparative analysis of survival outcomes between pancreatectomy and chemotherapy for elderly patients with adenocarcinoma of the pancreas. Cancer, 2016, 122, 3378-3385.	2.0	33
49	Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for colorectal cancer: choosing the right candidates. Expert Review of Anticancer Therapy, 2015, 15, 859-861.	1.1	1
50	Trends in the use of pre-operative radiation for adenocarcinoma of the pancreas in the United States. Hpb, 2015, 17, 542-550.	0.1	4
51	Perceptions of Contralateral Breast Cancer Risk: A Prospective, Longitudinal Study. Annals of Surgical Oncology, 2015, 22, 3846-3852.	0.7	22
52	Surgical Decision Making for Breast Cancer: Hitting the Sweet Spot Between Paternalism and Consumerism. Annals of Surgical Oncology, 2015, 22, 351-352.	0.7	7
53	Response. Journal of the National Cancer Institute, 2015, 107, dju508-dju508.	3.0	0
54	Response. Journal of the National Cancer Institute, 2015, 107, djv093-djv093.	3.0	0

#	Article	IF	CITATIONS
55	The Rise in Appendiceal Cancer Incidence: 2000–2009. Journal of Gastrointestinal Surgery, 2015, 19, 743-750.	0.9	134
56	Bilateral Mastectomy: Doubling Down on Complications?. Annals of Surgical Oncology, 2015, 22, 3407-3408.	0.7	4
57	Lymph Node Evaluation for Pancreatic Adenocarcinoma and Its Value as a Quality Metric. Journal of Gastrointestinal Surgery, 2015, 19, 2162-2170.	0.9	11
58	Lymph node evaluation for treatment of adenocarcinoma of the pancreas. Surgical Oncology, 2015, 24, 284-291.	0.8	12
59	Prophylactic mastectomy: Who needs it, when and why. Journal of Surgical Oncology, 2015, 111, 91-95.	0.8	20
60	The Emerging Role of Prophylactic Mastectomy. , 2015, , 129-136.		0
61	Neoadjuvant interferonâ€based chemoradiation for borderline resectable and locally advanced pancreas cancer: a Phase II pilot study. Hpb, 2014, 16, 131-139.	0.1	17
62	Contralateral prophylactic mastectomy: are we overtreating patients?. Expert Review of Anticancer Therapy, 2014, 14, 491-494.	1.1	6
63	An Individual Person Data Meta-Analysis of Preoperative Magnetic Resonance Imaging and Breast Cancer Recurrence. Journal of Clinical Oncology, 2014, 32, 392-401.	0.8	162
64	Survival Outcomes After Contralateral Prophylactic Mastectomy: A Decision Analysis. Journal of the National Cancer Institute, 2014, 106, dju160-dju160.	3.0	88
65	Short-Term Outcomes after Combined Colon and Liver Resection for Synchronous Colon Cancer Liver Metastases: A Population Study. Annals of Surgical Oncology, 2013, 20, 139-147.	0.7	36
66	Trends in Incidence and Management of Lobular Carcinoma In Situ: A Population-Based Analysis. Annals of Surgical Oncology, 2013, 20, 3240-3246.	0.7	58
67	Prospective Multicenter Trial Evaluating Balloon-Catheter Partial-Breast Irradiation for Ductal Carcinoma in Situ. International Journal of Radiation Oncology Biology Physics, 2013, 87, 494-498.	0.4	19
68	Minimally Invasive Inguinal Lymph Node Dissection (MILND) for Melanoma: Experience from Two Academic Centers. Annals of Surgical Oncology, 2013, 20, 340-345.	0.7	34
69	The association of preoperative breast magnetic resonance imaging and multiple breast surgeries among older women with early stage breast cancer. Breast Cancer Research and Treatment, 2013, 138, 137-147.	1.1	17
70	Rise of mastectomy. Journal of Surgical Oncology, 2013, 107, 563-564.	0.8	11
71	Variability of Preoperative Breast MRI Utilization among Older Women with Newly Diagnosed Early-stage Breast Cancer. Breast Journal, 2013, 19, 627-636.	0.4	20
72	Lymph Node Evaluation for Colon Cancer in an Era of Quality Guidelines: Who Improves?. Journal of Oncology Practice, 2013, 9, e164-e171.	2.5	26

#	Article	IF	CITATIONS
73	Contralateral Prophylactic Mastectomy: Perceptions Versus Reality. Annals of Internal Medicine, 2013, 159, 428.	2.0	6
74	Hospital Characteristics Associated With Maintenance or Improvement of Guideline-recommended Lymph Node Evaluation for Colon Cancer. Medical Care, 2013, 51, 60-67.	1.1	12
75	The rise in appendix cancer incidence: 2000-2009 Journal of Clinical Oncology, 2013, 31, e12506-e12506.	0.8	1
76	Omission of radiation therapy after breastâ€conserving surgery in the United States. Cancer, 2012, 118, 2004-2013.	2.0	43
77	Quality of Care along the Cancer Continuum: Does Receiving Adequate Lymph Node Evaluation for Colon Cancer Lead to Comprehensive Postsurgical Care?. Journal of the American College of Surgeons, 2012, 215, 400-411.	0.2	14
78	Is Breast Conservation Therapy Under Siege?. Breast Diseases, 2012, 23, 128-131.	0.0	1
79	Outcomes after Tumescence Technique versus Electrocautery Mastectomy. Annals of Surgical Oncology, 2012, 19, 2607-2611.	0.7	21
80	The Influence of Preoperative MRI on Breast Cancer Treatment. Annals of Surgical Oncology, 2012, 19, 536-540.	0.7	89
81	Do Hospital Attributes Predict Guideline-Recommended Gastric Cancer Care in the United States?. Annals of Surgical Oncology, 2012, 19, 365-372.	0.7	19
82	Prognosis for primary retroperitoneal sarcoma survivors. Cancer, 2012, 118, 3321-3329.	2.0	35
83	United States Trends in the Surgical Treatment of Primary Breast Cancer. World Journal of Surgery, 2012, 36, 1475-1479.	0.8	7
84	Who Receives Their Complex Cancer Surgery at Low-Volume Hospitals?. Journal of the American College of Surgeons, 2012, 214, 81-87.	0.2	98
85	Surgical treatment of lung cancer: Predicting postoperative morbidity in the elderly population. Journal of Thoracic and Cardiovascular Surgery, 2012, 143, 1314-1323.	0.4	93
86	Neoadjuvant interferon-based chemoradiation for locally advanced pancreas cancer: A phase II pilot study Journal of Clinical Oncology, 2012, 30, 266-266.	0.8	0
87	The Long-term Impact of Surgical Complications After Resection of Stage I Nonsmall Cell Lung Cancer. Annals of Surgery, 2011, 254, 368-374.	2.1	66
88	Severe Electrolyte Disturbances After Hyperthermic Intraperitoneal Chemotherapy: Oxaliplatin Versus Mitomycin C. Annals of Surgical Oncology, 2011, 18, 174-180.	0.7	34
89	Guideline Recommended Gastric Cancer Care in the Elderly: Insights into the Applicability of Cancer Trials to Real World. Annals of Surgical Oncology, 2011, 18, 26-33.	0.7	41
90	Preoperative Risk Assessment Among Women Undergoing Bilateral Prophylactic Mastectomy for Cancer Risk Reduction. Annals of Surgical Oncology, 2011, 18, 2515-2520.	0.7	3

#	Article	IF	Citations
91	Perceptions of Contralateral Breast Cancer: An Overestimation of Risk. Annals of Surgical Oncology, 2011, 18, 3129-3136.	0.7	133
92	Trends in the local treatment of breast cancer: Should we be worried?. Journal of Surgical Oncology, 2011, 103, 313-316.	0.8	17
93	Appendiceal carcinoid tumors: Predictors of lymph node metastasis and the impact of right hemicolectomy on survival. Journal of Surgical Oncology, 2011, 103, 39-45.	0.8	51
94	Conditional survival of extremity softâ€ŧissue sarcoma. Cancer, 2011, 117, 1055-1060.	2.0	25
95	Trends in the use of implantable accelerated partial breast irradiation therapy for early stage breast cancer in the United States. Cancer, 2011, 117, 3305-3310.	2.0	31
96	Association Between Lymph Node Evaluation for Colon Cancer and Node Positivity Over the Past 20 Years. JAMA - Journal of the American Medical Association, 2011, 306, 1089.	3.8	159
97	Random Physician Effect and Comparative Effectiveness of Treatment for Ductal Carcinoma In Situ. Journal of the National Cancer Institute, 2011, 103, 81-82.	3.0	2
98	Major Cancer Surgery in the Elderly. Annals of Surgery, 2010, 251, 311-318.	2.1	116
99	Author Reply: Contralateral Prophylactic Mastectomy Overtreatment: Expectations from Personal Genomics for Tailored Breast Cancer Surgery. Annals of Surgical Oncology, 2010, 17, 940-940.	0.7	3
100	Conditional Survival After Surgical Treatment of Melanoma: An Analysis of the Surveillance, Epidemiology, and End Results Database. Annals of Surgical Oncology, 2010, 17, 1662-1668.	0.7	31
101	Body Mass Index and Major Cancer Surgery Outcomes: Lack of Association or Need for Alternative Measurements of Obesity?. Annals of Surgical Oncology, 2010, 17, 2264-2273.	0.7	38
102	Extremity Soft Tissue Sarcoma Care in the Elderly: Insights into the Generalizability of NCI Cancer Trials. Annals of Surgical Oncology, 2010, 17, 1732-1738.	0.7	51
103	Controversies in Breast Surgery. Annals of Surgical Oncology, 2010, 17, 230-232.	0.7	9
104	The Increasing Use of Prophylactic Mastectomy in the Prevention of Breast Cancer. Current Oncology Reports, 2010, 12, 16-21.	1.8	73
105	Incorporating margin status information in treatment decisions for women with ductal carcinoma in situ: a decision analysis. Breast Cancer Research and Treatment, 2010, 124, 393-402.	1.1	1
106	Determination of the minimum number of lymph nodes to examine to maximize survival in patients with esophageal carcinoma: Data from the Surveillance Epidemiology and End Results database. Journal of Thoracic and Cardiovascular Surgery, 2010, 139, 612-620.	0.4	128
107	Variations in gastric cancer care. Cancer, 2010, 116, 465-475.	2.0	50
108	The Impact of Surgery, Radiation, and Systemic Treatment on Outcomes in Patients With Ductal Carcinoma In Situ. Journal of the National Cancer Institute Monographs, 2010, 2010, 130-133.	0.9	19

#	Article	IF	CITATIONS
109	The Impact of Sentinel Lymph Node Biopsy and Magnetic Resonance Imaging on Important Outcomes Among Patients With Ductal Carcinoma In Situ. Journal of the National Cancer Institute Monographs, 2010, 2010, 117-120.	0.9	6
110	Are Mastectomy Rates Really Increasing in the United States?. Journal of Clinical Oncology, 2010, 28, 3437-3441.	0.8	201
111	Ductal Carcinoma In Situ of the Breast: A Systematic Review of Incidence, Treatment, and Outcomes. Journal of the National Cancer Institute, 2010, 102, 170-178.	3.0	512
112	Re: Population-Based Study of Contralateral Prophylactic Mastectomy and Survival Outcomes of Breast Cancer Patients. Journal of the National Cancer Institute, 2010, 102, 1371-1372.	3.0	4
113	Association Between Patient and Tumor Characteristics With Clinical Outcomes in Women With Ductal Carcinoma In Situ. Journal of the National Cancer Institute Monographs, 2010, 2010, 121-129.	0.9	52
114	Ductal Carcinoma In Situ: Risk Factors and Impact of Screening. Journal of the National Cancer Institute Monographs, 2010, 2010, 113-116.	0.9	56
115	Increasing Rates of Contralateral Prophylactic Mastectomy Among Patients With Ductal Carcinoma In Situ. Journal of Clinical Oncology, 2009, 27, 1362-1367.	0.8	372
116	Lymph node evaluation is associated with improved survival after surgery for early stage gallbladder cancer. Surgery, 2009, 146, 706-713.	1.0	74
117	Laparoscopic Distal Pancreatectomy. Journal of the American College of Surgeons, 2009, 209, 758-765.	0.2	68
118	A Critical Analysis of the Surgical Management of Early-Stage Gallbladder Cancer in the United States. Journal of Gastrointestinal Surgery, 2009, 13, 722-727.	0.9	73
119	Increasing contralateral mastectomy use at diagnosis: Surgical prevention of contralateral breast cancer. Current Breast Cancer Reports, 2009, 1, 162-166.	0.5	1
120	Magnetic Resonance Imaging and Contralateral Prophylactic Mastectomy: The "No Más―Effect?. Annals of Surgical Oncology, 2009, 16, 1461-1462.	0.7	13
121	Patient and Surgeon Characteristics Associated with Increased Use of Contralateral Prophylactic Mastectomy in Patients with Breast Cancer. Annals of Surgical Oncology, 2009, 16, 2697-2704.	0.7	205
122	Factors and Choices Affecting the Trend Toward Increased Use of Contralateral Prophylactic Mastectomy. Breast Diseases, 2008, 19, 20-21.	0.0	0
123	Exposure–response relationships for oxaliplatin-treated colon cancer cells. Anti-Cancer Drugs, 2008, 19, 37-44.	0.7	24
124	Counseling breast cancer patients on contralateral prophylactic mastectomy: the physician's role. Oncology, 2008, 22, 545-8.	0.4	7
125	Contralateral prophylactic mastectomy for patients with unilateral breast cancer. Expert Review of Anticancer Therapy, 2007, 7, 1117-1122.	1.1	32
126	Increasing Use of Contralateral Prophylactic Mastectomy for Breast Cancer Patients: A Trend Toward More Aggressive Surgical Treatment. Journal of Clinical Oncology, 2007, 25, 5203-5209.	0.8	600

#	Article	IF	CITATIONS
127	Factors influencing the number of sentinel lymph nodes identified in patients with breast cancer. American Journal of Surgery, 2007, 194, 860-865.	0.9	16
128	Preoperative Staging and Postoperative Surveillance for Gastric Cancer. Surgical Oncology Clinics of North America, 2007, 16, 329-342.	0.6	25
129	Trends in the incidence and treatment of parathyroid cancer in the United States. Cancer, 2007, 109, 1736-1741.	2.0	255
130	Trends in the Treatment and Outcome of Pancreatic Cancer in the United States. Annals of Surgical Oncology, 2007, 14, 1320-1326.	0.7	131
131	Staged Laparoscopic Infusion of Hyperthermic Intraperitoneal Chemotherapy After Cytoreductive Surgery. Journal of Gastrointestinal Surgery, 2006, 10, 1038-1043.	0.9	21
132	Toxicity and Quality of Life after Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy. Annals of Surgical Oncology, 2006, 13, 1627-1632.	0.7	48
133	Inadequacy of Lymph Node Staging in Gastric Cancer Patients: A Population-Based Study. Annals of Surgical Oncology, 2005, 12, 981-987.	0.7	79
134	Intraoperative Subareolar Injection of 99mTc-Labeled Sulfur Colloid Results in Consistent Sentinel Lymph Node Identification. Annals of Surgical Oncology, 2005, 12, 167-172.	0.7	19
135	Factors predicting failure to identify a sentinel lymph node in breast cancer. Surgery, 2005, 138, 56-63.	1.0	76
136	Biopsy type does not influence sentinel lymph node status. American Journal of Surgery, 2005, 190, 551-556.	0.9	14
137	Effect of lymphoscintigraphy drainage patterns on sentinel lymph node biopsy in patients with breast cancer. American Journal of Surgery, 2005, 190, 557-562.	0.9	31
138	Surgeon and community factors affecting breast cancer sentinel lymph node biopsy. American Journal of Surgery, 2005, 190, 915-919.	0.9	23
139	Neoadjuvant Chemotherapy of Locally Advanced Breast Cancer: Predicting Response with in Vivo1H MR Spectroscopy—A Pilot Study at 4 T. Radiology, 2004, 233, 424-431.	3.6	304
140	Trends in the Treatment of Ductal Carcinoma In Situ of the Breast. Journal of the National Cancer Institute, 2004, 96, 443-448.	3.0	312
141	Sentinel Lymph Node Biopsy for Breast Cancer: Improvement in Results Over Time. Breast Journal, 2004, 10, 337-344.	0.4	12
142	Owen H Wangensteen, Jerome A Urban, and the pursuit of extraaxillary lymph node metastases from breast cancer. Journal of the American College of Surgeons, 2004, 199, 636-643.	0.2	2
143	Long-term Survival After An Aggressive Surgical Approach in Patients With Breast Cancer Hepatic Metastases. Annals of Surgical Oncology, 2004, 11, 869-874.	0.7	177
144	Validation of Subareolar and Periareolar Injection Techniques for Breast Sentinel Lymph Node Biopsy. Archives of Surgery, 2004, 139, 614.	2.3	80

#	Article	IF	Citations
145	Technical advances in sentinel lymph node biopsy for breast cancer. American Surgeon, 2004, 70, 407-13.	0.4	34
146	Surgical therapy for anorectal melanoma. Journal of the American College of Surgeons, 2003, 196, 206-211.	0.2	132
147	Frequency of sentinel lymph node metastases in patients with favorable breast cancer histologic subtypes. American Journal of Surgery, 2002, 184, 492-498.	0.9	55
148	A review of technical aspects of sentinel lymph node identification for breast cancer 11No competing interests declared Journal of the American College of Surgeons, 2002, 195, 261-268.	0.2	20
149	The effect of prior breast biopsy method and concurrent definitive breast procedure on success and accuracy of sentinel lymph node biopsy. Annals of Surgical Oncology, 2002, 9, 272-277.	0.7	83
150	Subareolar injection of 99mTc facilitates sentinel lymph node identification. Annals of Surgical Oncology, 2002, 9, 77-81.	0.7	92
151	Comparison of side effects between sentinel lymph node and axillary lymph node dissection for breast cancer., 2002, 9, 745.		8
152	Dermal Injection of Radioactive Colloid Is Superior to Peritumoral Injection for Breast Cancer Sentinel Lymph Node Biopsy: Results of a Multiinstitutional Study. Annals of Surgery, 2001, 233, 676-687.	2.1	244
153	Defining the Optimal Surgeon Experience for Breast Cancer Sentinel Lymph Node Biopsy: A Model for Implementation of New Surgical Techniques. Annals of Surgery, 2001, 234, 292-300.	2.1	202
154	Sentinel lymph node biopsy for breast cancer: impact of the number of sentinel nodes removed on the false-negative rate1 1No competing interests declared Journal of the American College of Surgeons, 2001, 192, 684-689.	0.2	190
155	Educating Patients on Sentinel Lymph Node Dissection for Breast Cancer. Cancer Practice, 2001, 9, 92-96.	0.8	6
156	Preoperative Lymphoscintigraphy for Breast Cancer Does Not Improve the Ability to Identify Axillary Sentinel Lymph Nodes. Annals of Surgery, 2000, 231, 724-731.	2.1	161
157	Sentinel Lymph Node Biopsy for Breast Cancer: A Suitable Alternative to Routine Axillary Dissection in Multi-Institutional Practice When Optimal Technique Is Used. Journal of Clinical Oncology, 2000, 18, 2560-2566.	0.8	556
158	Practical guidelines for optimal gamma probe detection of sentinel lymph nodes in breast cancer: Results of a multi-institutional study. Surgery, 2000, 128, 139-144.	1.0	176
159	Neoadjuvant chemoradiation for extrahepatic cholangiocarcinoma. American Journal of Surgery, 1997, 174, 605-609.	0.9	199
160	Ex vivo expansion of tumor-draining lymph node cells using compounds which activate intracellular signal transduction. I. Characterization and in vivo anti-tumor activity of glioma-sensitized lymphocytes. Journal of Neuro-Oncology, 1997, 32, 19-28.	1.4	17
161	Repeat hepatic resection as effective treatment for recurrent colorectal liver metastases. Annals of Surgical Oncology, 1997, 4, 125-130.	0.7	99
162	Ability of low-dose cyclophosphamide to overcome metastasis-induced immunosuppression. Annals of Surgical Oncology, 1994, 1, 53-58.	0.7	14

TODD M TUTTLE

#	Article	IF	CITATIONS
163	Postischemic extremities exhibit immediate release of tumor necrosis factor. Journal of Vascular Surgery, 1994, 20, 474-481.	0.6	44
164	Activation of CD8+ Murine T Cells from Tumor-Draining Lymph Nodes by Phorbol Dibutyrate plus Calcium Ionophore. Journal of Immunotherapy, 1992, 12, 32-40.	1.2	7
165	Bryostatin 1 Activates T Cells That Have Antitumor Activity. Journal of Immunotherapy, 1992, 12, 75-81.	1.2	18
166	Bryostatin 1-activated T cells can traffic and mediate tumor regression. Journal of Surgical Research, 1992, 52, 543-548.	0.8	23
167	Evidence for Cyclophosphamide-Induced Transitional Cell Carcinoma in a Renal Transplant Patient. Journal of Urology, 1988, 140, 1009-1011.	0.2	30